Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

The present study of the regulatory T phenotype of Szary cells led to the discovery of the expression of GARP (LRRC32) by Szary cells. GARP has also been shown to be overexpressed in samples from patients with acute lymphoblastic leukemia. GARP therefore appears as a diagnostic marker, for monitoring T-cell malignancies, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of T-cell malignancies.

The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to L1-CAM (CD171), to a polynucleotide encoding at least one variable heavy chain sequence and/or at least one variable light chain sequence as in the antibody or an antigen binding fragment thereof of the present invention, to a host cell comprising the polynucleotide of the present invention, to an immunoconjugate comprising an antibody or an antigen-fragment binding thereof of the present invention and an active agent, to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof of the present invention, or the immunoconjugate of the present invention, and their use in treatment and/or diagnosis. The antibodies, antigen-binding fragments thereof, the immunoconjugates and the pharmaceutical compositions described herein are particularly useful in treatment or diagnosis of an L1-CAM (CD171) associated cancer.

A method for predicting disease incidence, progression, aggressiveness, and prognosis of brain tumors including gliomas and astrocytomas using palladin as a marker. Palladin expression is also disclosed as a therapeutic target for the treatment of brain tumors, in addition to a method of treating brain tumors by regulating and/or modifying and/or deleting palladin expression. In embodiments, palladin is targeted by therapeutic agents that are systemically or locally administered. Targeted glioma tumors include astrocytomas, oligodendrogliomas, and glioblastomas. The disclosure provides that palladin expression can be linked to adult astrocytoma progression and is associated with a worsening prognosis.

Provided are novel multispecific antibodies comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a third antigen-binding region capable of binding specifically to transferrin receptor (TfR).

Methods are provided for diagnosing, detecting, or prognosticating a GEP-NEN based on the expression level score of biomarkers exhibiting differential expression in subjects having a GEP-NEN relative to a reference or control sample. The invention also provides compositions and kits comprising these biomarkers and methods of using these biomarkers in subsets or panels thereof to diagnose, classify, and monitor GEP-NEN and types of GEP-NEN. The methods and compositions provided herein may be used to diagnose or classify a subject as having a GEP-NEN, to distinguish between different stages of GEP-NENs, e.g., stable or progressive, to provide a measure of risk of developing a progressive GEP-NEN, and to gauge the completeness of treatments for GEP-NEN including, but not limited to surgery and somatostatin therapy.

Provided herein are antibody molecules that bind specifically to C-MET and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.

This document relates to methods and materials involved in assessing and/or treating a mammal having cancer (e.g., lymphoma). For example, methods and materials that can be used to determine if a mammal (e.g., a human) having cancer (e.g., lymphoma) is likely to respond to or has a cancer or a gut microbiome that makes that mammal more responsive to a particular cancer treatment are provided. Methods and materials for treating a mammal having cancer (e.g., lymphoma) are also provided.

This application is directed to methods and compositions related to the treatment and diagnosis of adenocarcinomas, such as adenoid cystic carcinoma (ACC). The methods and compositions related to the use of CD49f, TP63, and/or KIT/CD117 cell-surface markers for subtyping the cancer cells. One method involves using a retinoic acid receptor/retinoid-X receptor inhibitor to inhibit the differentiation of myoepithelial-like cells into ductal-like cells. Another method involves using a retinoic acid receptor/retinoid-X receptor inhibitor to selectively reduce the viability of ductal-like cells.

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.